Claims:

1. A compound of formula (I):



(I)

wherein:

X is C, O, NR^1, SO_2 or S;

Ar^1 is a 5- or 6-membered aromatic or heterocyclic ring optionally substituted with 0, 1, 2, or 3 R^e moieties, said ring having 0, 1, 2 or 3 nitrogen, oxygen or sulfur atoms, but no more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom;

R^1 is H, C_{1-3}alkylC_{3-6}cycloalkyl, C_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}alkynyl C_{3-6}cycloalkyl, C_{2-4}alkylNR^aR^b, C_{1-4}alkyl$C(=O)R^d$; or C_{1-3}alkylphenyl substituted with 0, 1, 2 or 3 R^e;

R^a and R^b are at each occurrence independently selected from H, C_{1-4}alkyl or C_{3-6}cycloalkyl, or R^a and R^b and the N to which they are attached in combination form a 5 or 6-membered N-linked heterocycle having 2 nitrogen atoms, wherein the non-linked nitrogen is substituted with R^c or 1 nitrogen and 1 oxygen, ring atoms wherein there is no non-linked nitrogen;

R^c is, at each occurrence independently selected from H, C_{1-3}alkyl, or substituted phenyl with 0, 1, 2, or 3 R^e;

R^d is, at each occurrence independently selected from C_{1-3}alkyl, hydroxy, C_{1-3}alkoxy, or NR^aR^b;

R^e is, at each occurrence independently selected from H, OH, F, Cl, Br, I, CN, NO_2, CF_3, C_{1-6}alkyl, or C_{1-6}alkoxy;

R^2 and R^3 are at each occurrence independently selected from H, C_{1-6}alkyl, C_{4-6} cycloalkyl, aryl, or heteroaryl, or R^2 and R^3 in combination form a fused phenyl or cyclohexyl moiety that may be substituted with 0, 1 or 2 R^f moieties,

R^f is NO_2, F, Cl, Br, I, CF_3, CN, C_{1-6}alkyl, or C_{1-6}alkoxy;

R^4 is H, CHR^7R^8, 5- or 6- membered cycloalkyl, 5- or 6- membered heterocyclic, 5 or 6- membered aromatic ring optionally substituted with 0, 1, or 2 R^f moities, said heterocyclic ring having 0, 1, 2 or 3 nitrogen, oxygen or sulfur atoms, but no more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom;

R^5 is C_{1-3}alkylR^9 or $CH(OH)R^{10}$;

R^7 and R^8 are, at each occurrence are independently selected from H, C_{1-4}alkyl, OH, SH, CH_2SCH_3, $CONH_2$, CH_2CONH_2, CO_2H, CH_2CO_2H, $(CH_2)_3NHCH(NH_2)_2$, C_{1-4}alkylamine, indole, imidazole, phenyl or hydroxyphenyl or R^7 and R^8 in combination form a 6-membered aromatic or heterocyclic ring optionally substituted with 0, 1 or 2 R^f moieties said heterocyclic ring having 0, 1, 2 or 3 nitrogen, oxygen or sulfur atoms, but no more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom;

R^9 is phenyl substituted with 0, 1, 2 or 3 R^e;

R^{10} is alkyl or R^9;

or a pharmaceutically acceptable salt thereof.

2. A compound of claim 1,

wherein:

X is C, O, NR^1, SO_2 or S;

Ar^1 is a 5- or 6-membered aromatic or heterocyclic ring optionally substituted with 0, 1, 2, or 3 R^e moieties, said ring having 0, 1, or 2 nitrogen, oxygen or sulfur atoms, but no more than 2 oxygen atoms or 1 oxygen and 1 sulfur atom;

R^1 is H, C_{1-3}alkylC_{3-6}cycloalkyl, C_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}alkynyl, C_{3-6}cycloalkyl, C_{2-4}alkylNR^aR^b, C_{1-4}alkyl$C(=O)R^d$; or C_{1-3}alkylphenyl substituted with 0, 1, or 2 R^e;

R^a and R^b are, at each occurrence independently selected from H, C_{1-4}alkyl or C_{3-6}cycloalkyl, or R^a and R^b and the N to which they are attached in combination form a 6-membered N-linked heterocycle having 2 nitrogen atoms, wherein the non-linked nitrogen is substituted with R^c or 1 nitrogen and 1 oxygen, ring atoms wherein there is no non-linked nitrogen;

R^c is, at each occurrence independently selected from H, C_{1-3}alkyl, or phenyl;

R^d is, at each occurrence independently selected from C_{1-3}alkyl, or NR^aR^b;

R^e is, at each occurrence independently selected from H, OH, F, Cl, Br, I, CN, NO_2, CF_3, C_{1-3}alkyl, or C_{1-3}alkoxy;

R^2 and R^3 are at each occurrence independently selected from H, C_{1-6}alkyl, C_{4-6} cycloalkyl, or aryl, or R^2 and R^3 in combination form a fused phenyl moiety that may be substituted with 0, 1 or 2 R^f moieties,

R^f is NO_2, F, Cl, Br, I, CF_3, CN, C_1-3alkyl, or C_1-3alkoxy;

R^4 is H, CHR^7R^8, 6- membered cycloalkyl, or 6- membered heterocyclic, or 6-membered aromatic ring optionally substituted with 0, 1, or 2 R^f moities, said heterocyclic ring having 0, 1, 2 or 3 nitrogen, oxygen or sulfur atoms, but no more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom;

R^5 is C_{1-3}alkylR^9 or $CH(OH)R^{10}$;

R^7 and R^8 are, at each occurrence independently selected from H, C_{1-4}alkyl, OH, $CONH_2$, CH_2CONH_2, CO_2H, CH_2CO_2H, $(CH_2)_3NHCH(NH_2)_2$, C_{1-4}alkylamine, indole, imidazole, phenyl or hydroxyphenyl or R^7 and R^8 in combination form a 6-membered aromatic or heterocyclic ring optionally substituted with 0, 1 or 2 R^f moieties said heterocyclic ring having 0, 1, 2 or 3 nitrogen, oxygen or sulfur atoms, but no more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom;

R^9 is phenyl substituted with 0, 1, or 2 R^e;

R^{10} is alkyl or R^9.

3. A compound of claim 1,

wherein:

X is C, O, NR^1, SO_2 or S;

Ar^1 is a 5- or 6-membered aromatic or heterocyclic ring optionally substituted with 0, 1, 2, or 3 R^e moieties, said ring having 0, 1, or 2 nitrogen, oxygen or sulfur atoms, but no more than 2 oxygen atoms or 1 oxygen and 1 sulfur atom;

R^1 is H, C_{1-3}alkylC_{3-6}cycloalkyl, C_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}alkynyl C_{3-6}cycloalkyl, C_{2-4}alkylNR^aR^b, C_{1-4}alkyl$C(=O)R^d$; or C_{1-3}alkylphenyl substituted with 0, 1, or 2 R^e;

R^a and R^b are, at each occurrence independently selected from H, C_{1-4}alkyl or C_{3-6}cycloalkyl, or R^a and R^b and the N to which they are attached in combination form a 5-membered N-linked heterocycle having 2 nitrogen atoms, wherein the non-linked nitrogen is substituted with R^c or 1 nitrogen and 1 oxygen, ring atoms wherein there is no non-linked nitrogen;

R^c is, at each occurrence independently selected from H, C_{1-3}alkyl, phenyl;

R^d is, at each occurrence independently selected from C_{1-3}alkyl or NR^aR^b;

R^e is, at each occurrence independently selected from H, OH, F, Cl, Br, I, CN, NO_2, CF_3, C_{1-6}alkyl, or C_{1-6}alkoxy;

R^2 and R^3 are at each occurrence independently selected from H, C_{1-6}alkyl, C_{4-6} cycloalkyl or aryl or R^2 and R^3 in combination form a fused phenyl moiety that may be substituted with 0, 1 or 2 R^f moieties,

R^f is H, NO_2, F, Cl, Br, I, CF_3, C_{1-6}alkyl, or C_{1-6}alkoxy;

R^4 is H, CHR^7R^8, or 6- membered heterocyclic, or 6- membered aromatic ring optionally substituted with 0, 1, or 2 R^f moities, said heterocyclic ring having 0, 1, 2 or 3 nitrogen, oxygen or sulfur atoms, but no more than 2 oxygen atoms or 2 sulfur atoms or 1 oxygen and 1 sulfur atom;

R^4 is H or CHR^7R^8;

R^5 is C_{1-3}alkylR^9 or $CH(OH)R^{10}$;

n is 0, 1 or 2;

R^7 and R^8 are, at each occurrence independently selected from H, C_{1-4}alkyl, OH, $CONH_2$, CH_2CONH_2, CO_2H, CH_2CO_2H, $(CH_2)_3NHCH(NH_2)_2$, C_{1-4}alkylamine, indole, imidazole, phenyl or hydroxyphenyl or R^7 and R^8 in combination form a 6-membered aromatic or heterocyclic ring optionally substituted with 0, 1 or 2 R^f moieties said heterocyclic ring having 0, 1, or 2 nitrogen, oxygen or sulfur atoms;

R^9 is phenyl substituted with 1, or 2 R^e;

R^{10} is alkyl or phenyl substituted with 1, or 2 R^e.

4. A compound of claim 1,

wherein:

X is C, O, NR^1, SO_2 or S;

Ar^1 is a 5- or 6-membered aromatic or heterocyclic ring optionally substituted with 0, 1, 2, or 3 R^e moieties, said ring having 0, 1, or 2 nitrogen, oxygen or sulfur atoms, but no more than 1 oxygen and 1 sulfur atom;

R^1 is H, C_{1-3}alkylC_{3-6}cycloalkyl, C_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}alkynyl C_{3-6}cycloalkyl, C_{2-4}alkylNR^aR^b, C_{1-4}alkyl$C(=O)R^d$; or C_{1-3}alkylphenyl substituted with 0, or 1 R^e;

R^a and R^b are, at each occurrence independently selected from H, C_{1-4}alkyl or C_{5-6}cycloalkyl, or R^a and R^b and the N to which they are attached in combination form a 6-membered N-linked heterocycle having 2 nitrogen atoms, wherein the non-linked nitrogen is

substituted with R^c or 1 nitrogen and 1 oxygen, ring atoms wherein there is no non-linked nitrogen;

R^c is, at each occurrence independently selected from H, C_{1-3}alkyl;

R^d is, at each occurrence independently selected from C_{1-3}alkyl;

R^e is, at each occurrence independently selected from H, OH, F, Cl, Br, I, CN, NO_2, CF_3, C_{1-6}alkyl;

R^2 and R^3 are at each occurrence independently selected from H, C_{1-6}alkyl, or R^2 and R^3 in combination form a fused phenyl moiety that may be substituted with 0, 1 or 2 R^f moieties,

R^f is H, F, Cl, Br, I, CF_3, C_{1-6}alkyl;

R^4 is H, CHR^7R^8, or 6- membered heterocyclic, or 6- membered aromatic ring optionally substituted with 0, 1, or 2 R^f moities, said heterocyclic ring having 0, 1, or 2 nitrogen, oxygen or sulfur atoms;

R^5 is C_{1-3}alkylR^9 or $CH(OH)R^{10}$;

n is 0, 1 or 2;

R^7 and R^8 are, at each occurrence independently selected from H, C_{1-4}alkyl, OH, $CONH_2$, CH_2CONH_2, CO_2H, CH_2CO_2H, $(CH_2)_3NHCH(NH_2)_2$, C_{1-4}alkylamine, indole, imidazole, phenyl or hydroxyphenyl or R^7 and R^8 in combination form a 6-membered aromatic or heterocyclic ring optionally substituted with 0, 1 or 2 R^f moieties said heterocyclic ring having 0, 1, or 2 nitrogen, or oxygen atoms;

R^9 is phenyl substituted with 1, or 2 R^e;

R^{10} is alkyl or R^9.

5. A compound of claim 1, wherein:

X is C, O, SO_2 or S;

Ar^1 is a 5- or 6-membered aromatic or heterocyclic ring optionally substituted with 0, 1, or 2 R^e moieties, said ring having 0, 1, or 2 nitrogen, oxygen or sulfur atoms;

R^1 is H, C_{1-3}alkylC_{3-6}cycloalkyl, C_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}alkynyl C_{3-6}cycloalkyl, C_{2-4}alkylNR^aR^b, C_{1-4}alkyl$C(=O)R^d$;

R^a and R^b are, at each occurrence independently selected from H, C_{1-4}alkyl or C_{5-6}cycloalkyl, or R^a and R^b and the N to which they are attached in combination form a 6-membered N-linked heterocycle having 2 nitrogen atoms, wherein the non-linked nitrogen is

substituted with R^c or 1 nitrogen and 1 oxygen, ring atoms wherein there is no non-linked nitrogen;

R^d is, at each occurrence independently selected from C_{1-3}alkyl;

R^e is, at each occurrence independently selected from H, OH, F, Cl, Br, I, NO_2, CF_3, or C_{1-6}alkyl;

R^2 and R^3 are at each occurrence independently selected from C_{1-6}alkyl or R^2 and R^3 in combination form a fused phenyl moiety that may be substituted with 0, 1 or 2 R^f moieties,

R^f is H, F, Cl, Br, I, CF_3;

R^4 is H, CHR^7R^8, or 6- membered heterocyclic, or 6- membered aromatic ring optionally substituted with 0, 1, or 2 R^f moities, said heterocyclic ring having 0, 1, or 2 nitrogen, or oxygen atoms;

R^5 is C_{1-3}alkylR^9 or $CH(OH)R^{10}$;

R^7 and R^8 are, at each occurrence independently selected from H, C_{1-4}alkyl, OH, $CONH_2$, CH_2CONH_2, CO_2H, C_{1-4}alkylamine, phenyl or hydroxyphenyl or R^7 and R^8 in combination form a 6-membered aromatic or heterocyclic ring optionally substituted with 0, 1 or 2 R^f moieties said heterocyclic ring having 0, 1, or 2 nitrogen, or oxygen atoms;

R^9 is phenyl substituted with 1, or 2 R^e;

R^{10} is alkyl or R^9.

6. A compound of claim 1, wherein:

X is C, O, SO_2 or S;

Ar^1 is a 6-membered aromatic or heterocyclic ring optionally substituted with 0, 1, or 2 R^e moieties, said ring having 0, or 1 nitrogen, oxygen or sulfur atoms;

R^1 is H, C_{1-3}alkylC_{3-6}cycloalkyl, C_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}alkynyl C_{3-6}cycloalkyl, C_{2-4}alkylNR^aR^b, C_{1-4}alkyl$C(=O)R^d$;

R^a and R^b are, at each occurrence independently selected from H, C_{1-4}alkyl or C_{5-6}cycloalkyl or R^a and R^b and the N to which they are attached in combination form a 6-membered N-linked heterocycle having 1 nitrogen and 1 oxygen, ring atom, wherein there is no non-linked nitrogen;

R^d is, at each occurrence independently selected from C_{1-3}alkyl;

R^e is, at each occurrence independently selected from H, OH, F, Cl, Br, I, CF_3;

R^2 and R^3 are combined to form a fused phenyl moiety substituted with 0, 1 or 2 R^f moieties,

R^f is H, F, Cl, Br, I, or CF_3;

R^4 is H, CHR^7R^8, or 6- membered heterocyclic, or 6- membered aromatic ring optionally substituted with 0, 1, or 2 R^f moities, said heterocyclic ring having 0, or 1, nitrogen, or oxygen atoms;

R^5 is C_{1-3}alkylR^9 or $CH(OH)R^{10}$;

R^7 and R^8 are, at each occurrence independently selected from H, OH, or R^7 and R^8 in combination form a 6-membered aromatic or heterocyclic ring optionally substituted with 0, 1 or 2 R^f moieties said heterocyclic ring having 0, or 1, nitrogen, or oxygen atoms;

R^9 is phenyl substituted with 2 R^e;

R^{10} is phenyl substituted with 2 R^e.

7. A compound of claim 1, wherein:

X is C, O, or S;

Ar^1 is a 6-membered aromatic or heterocyclic ring optionally substituted with 0, 1, or 2 R^e moieties, said ring having having 0, or 1 nitrogen, or oxygen atoms;

R^1 is H, C_{1-3}alkylC_{3-6}cycloalkyl, C_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}alkynyl C_{3-6}cycloalkyl, C_{2-4}alkylNR^aR^b;

R^a and R^b are, at each occurrence independently selected from H, C_{1-4}alkyl or C_{5-6}cycloalkyl or R^a and R^b and the N to which they are attached in combination form a 6-membered N-linked heterocycle having 1 nitrogen and 1 oxygen, ring atom, wherein there is no non-linked nitrogen;

R^2 and R^3 are combined to form a fused phenyl moiety substituted with 0,1 or 2 R^f;

R^e is, at each occurrence independently selected from H, OH, F, Cl, Br, I, CF_3;

R^f is F or Cl;

R^4 is H, CHR^7R^8, or 6- membered aromatic ring optionally substituted with 0, 1, or 2 R^f moities;

R^5 is C_{1-3}alkylR^9 or $CH(OH)R^{10}$;

R^7 and R^8 are, at each occurrence independently selected from H, OH, or R^7 and R^8 in combination form a 6-membered aromatic ring optionally substituted with 0, 1 or 2 R^f moieties

R^7 and R^8 are, at each occurrence independently selected from H or OH;

R^9 is phenyl substituted with 2 R^e;

R^{10} is phenyl substituted with 2 R^e.

8. A compound of claim 1, wherein:

X is O or C or S;

Ar^1 is a 6-membered aromatic or heterocyclic ring optionally substituted with 0, 1, or 2 R^e moieties, said ring having having 0, or 1 nitrogen atom;

R^1 is H, C_{1-3}alkylC_{3-6}cycloalkyl, C_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}alkynyl C_{3-6}cycloalkyl, C_{2-4}alkylNR^aR^b;

R^a and R^b are, at each occurrence independently selected from H, C_{1-4}alkyl or C_{5-6}cycloalkyl or R^a and R^b and the N to which they are attached in combination form a 6-membered N-linked heterocycle having 1 nitrogen and 1 oxygen, ring atom, wherein there is no non-linked nitrogen;

R^2 and R^3 are combined to form a fused phenyl moiety substituted with 0, 1 or 2 R^f wherin R^f is F or Cl;

R^4 is H, CH_3, or a 6-membered aromatic ring optionally substituted with 0, 1, or 2 R^f moities;

R^5 is C_{1-3}alkylR^9;

R^e is, at each occurrence independently selected from H, OH, F, Cl, Br, I, CF_3;

R^9 is phenyl substituted with 2 R^e.

9. A compound of claim 1, wherein:

X is O or C;

Ar^1 is a 6-membered aromatic ring optionally substituted with 0, 1, or 2 R^e moieties;

R^1 is H, C_{1-3}alkylC_{3-6}cycloalkyl, C_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}alkynyl C_{3-6}cycloalkyl, C_{2-4}alkylNR^aR^b;

R^a and R^b are, at each occurrence independently selected from H, C_{1-4}alkyl or C_{5-6}cycloalkyl or R^a and R^b and the N to which they are attached in combination form a 6-membered N-linked heterocycle having 1 nitrogen and 1 oxygen, ring atom, wherein there is no non-linked nitrogen;

R^2 and R^3 are combined to form a fused phenyl moiety substituted with 0,1 or 2 R^f wherin R^f is F or Cl;

R^4 is H, CH_3, or a 6-membered aromatic ring optionally substituted with 0, 1, or 2 R^f moities;

R^5 is C_{1-3}alkylR^9;

R^e is, at each occurrence independently selected from H, OH, F, Cl, Br, I, CF_3;

R^9 is phenyl substituted with 2 R^e.

10. A compound of claim 1, wherein:

X is O;

Ar^1 is a 6-membered aromatic ring optionally substituted with 0, 1, or 2 R^e moieties;

R^1 is C_{1-3}alkylC_{3-6}cycloalkyl, C_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}alkynyl;

R^2 and R^3 are combined to form a fused phenyl moiety substituted with 0,1 or 2 R^f wherin R^f is F or Cl;

R^4 is H, CH_3, or a 6-membered aromatic ring optionally substituted with 0, 1, or 2 R^f moities;

R^5 is C_{1-3}alkylR^9;

R^e is, at each occurrence independently selected from H, OH, F, Cl, Br, I, CF_3;

R^9 is phenyl substituted with 2 R^e.

11. A compound of claim 1, wherein X is C, O, SO_2 or S.

12. A compound of claim 1, wherein:

Ar^1 is a 5-or 6-membered aromatic or heterocyclic ring optionally substituted with 0 or 1 R^e.

13. A compound of claim 1, wherein:

R^1 is C_{1-3}alkylC_{3-6}cycloalkyl, C_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}alkynyl.

14. A compound of claim 1, wherein:

R^a and R^b are, at each occurrence independently selected from H, C_{1-4}alkyl or C_{5-6}cycloalkyl or R^a and R^b and the N to which they are attached in combination form a 6-membered N-linked heterocycle having 1 nitrogen and 1 oxygen, ring atom, wherein there is no non-linked nitrogen.

15. A compound of claim 1, wherein:

R^2 and R^3 are combined to form a fused phenyl moiety substituted with 0, 1 or 2 R^f.

16. A compound of claim 1, wherein R^e is, at each occurrence independently selected from F or Cl.

17. A compound of claim 1, wherein R^f is F or Cl.

18. A compound of claim 1, wherein R^4 is H or CHR^7R^8 or a 6-membered aromatic ring optionally substituted with 0, 1, or 2 R^f moities wherein R^7 and R^8 are, at each occurrence independently selected from H or OH.

19. A compound of claim 1, wherein R^4 is a 6-membered aromatic ring optionally substituted with 0, 1, or 2 R^f moities wherein R^f is halo.

20. A compound of claim 1, wherein R^5 is C_{1-3}alkylR^9 or $CH(OH)R^{10}$.

21. A compound of claim 1, wherein R^7 and R^8 are, at each occurrence independently selected from H or OH.

22. A compound of claim 1, wherein R^9 is phenyl substituted with 2 R^e.

23. A compound of claim 1, wherein R^{10} is phenyl substituted with 2 R^e.

24. A compound of formula (I) selected from:
N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*R*)-2-(2,5-difluorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;
N^1-[(2*R*,3*R*)-5-cyclohexyl-2-(2,5-difluorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N^2-[(3,5-difluorophenyl)acetyl]-L-alaninamide;
N^2-[(3,5-difluorophenyl)acetyl]-N^1-{(2*R*,3*R*)-2-(2,5-difluorophenyl)-5-[2-(dimethylamino)ethyl]-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl}-L-alaninamide;
N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*R*)-2-(2,5-difluorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-serinamide;
N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*R*)-2-(2,5-difluorophenyl)-5-methyl-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*S*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(6*R*,7*R*)-5-oxo-7-phenyl-1,4-thiazepan-6-yl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(3*S*,4*R*)-8-fluoro-2-oxo-4-phenyl-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*R*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N^1-[(2*R*,3*R*)-2-(3,4-dichlorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N^2-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^1-[(2*R*,3*R*)-2-(4-chlorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N^2-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*R*)-2-(4-methylphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N^1-[(2*R*,3*R*)-7-chloro-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N^2-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^1-{(2*R*,3*R*)-7-chloro-5-[2-(dimethylamino)ethyl]-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl}-N^2-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^1-[(2*R*,3*R*)-2-(3-chlorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N^2-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*R*)-2-(3,5-difluorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*R*)-2-(3,5-difluorophenyl)-5-methyl-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*R*)-2-(2-fluorophenyl)-5-methyl-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N^1-{(2*R*,3*R*)-2-(3-chlorophenyl)-5-[2-(dimethylamino)ethyl]-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl}-N^2-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*R*)-2-(2,5-difluorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-D-serinamide;

N^1-[(2*R*,3*R*)-2-(3-chlorophenyl)-5-methyl-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N^2-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*R*)-5-methyl-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N^1-[(2*R*,3*R*)-5-cyclohexyl-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N^2-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^1-[(2*R*,3*R*)-7-chloro-5-cyclohexyl-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N^2-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(6*R*,7*R*)-7-(1-naphthyl)-5-oxo-1,4-thiazepan-6-yl]-L-alaninamide;

(2*S*)-2-{[(3,5-difluorophenyl)acetyl]amino}-N-[(6*R*,7*R*)-7-(1-naphthyl)-5-oxo-1,4-thiazepan-6-yl]-2-phenylacetamide;

(2*S*)-2-hydroxy-4-methyl-N-((1*S*)-2-{[(6*R*,7*R*)-7-(1-naphthyl)-5-oxo-1,4-thiazepan-6-yl]amino}-2-oxo-1-phenylethyl)pentanamide;

(2*S*)-2-hydroxy-4-methyl-N-((1*S*)-2-oxo-2-{[(2*R*,3*S*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]amino}-1-phenylethyl)pentanamide;

N^2-[(2*S*)-2-hydroxy-4-methylpentanoyl]-N^1-[(2*R*,3*S*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-leucinamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(6*S*,7*R*)-4-methyl-5-oxo-7-phenyl-1,4-oxazepan-6-yl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*S*,6*S*,7*R*)-4-methyl-5-oxo-2,7-diphenyl-1,4-oxazepan-6-yl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(6*R*,7*R*)-4-methyl-5-oxo-7-phenyl-1,4-thiazepan-6-yl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(3*R*,6*S*,7*R*)-4-methyl-5-oxo-3,7-diphenyl-1,4-oxazepan-6-yl]-L-alaninamide;;

(2*S*)-2-hydroxy-4-methyl-N-((1*S*)-2-{[(6*S*,7*R*)-4-methyl-5-oxo-7-phenyl-1,4-oxazepan-6-yl]amino}-2-oxo-1-phenylethyl)pentanamide;

(2*S*)-2-{[(3,5-difluorophenyl)acetyl]amino}-N-[(6*S*,7*R*)-4-methyl-5-oxo-7-phenyl-1,4-oxazepan-6-yl]-2-phenylacetamide;

(2*S*)-2-cyclohexyl-2-{[(3,5-difluorophenyl)acetyl]amino}-N-[(3*R*,6*S*,7*R*)-4-methyl-5-oxo-3,7-diphenyl-1,4-oxazepan-6-yl]acetamide;

(2*S*)-2-{[(3,5-difluorophenyl)acetyl]amino}-N-[(3*R*,6*S*,7*R*)-4-methyl-5-oxo-3,7-diphenyl-1,4-oxazepan-6-yl]-2-phenylacetamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(6*S*,7*R*)-4-(4-methoxybenzyl)-5-oxo-7-phenyl-1,4-oxazepan-6-yl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*S*,5aR,9aR)-5-methyl-4-oxo-2-phenyldecahydro-1,5-benzoxazepin-3-yl]-L-alaninamide;

(2*S*)-2-{[(3,5-difluorophenyl)acetyl]amino}-N-[(6*S*,7*R*)-4-(4-methoxybenzyl)-5-oxo-7-phenyl-1,4-oxazepan-6-yl]-2-phenylacetamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*R*)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N^1-[(2*R*,3*R*)-7-chloro-2-(2,5-difluorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N^2-[(2*S*)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-L-alaninamide;

N^2-[(2*S*)-2-hydroxy-4-methyl-1-oxopentyl]-N^1-[(2*R*,3*S*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*S*)-5-methyl-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-alaninamide;

N^1-[(2*R*,3*R*)-7-chloro-2-(2,5-difluorophenyl)-5-methyl-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N^2-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-{(2*R*,3*S*)-5-[2-(dimethylamino)ethyl]-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl}-L-alaninamide;

N^1-[(2*R*,3*R*)-7-chloro-2-(2,5-difluorophenyl)-4-oxo-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N^2-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(6*R*,7*R*)-5-oxo-7-phenyl-1,4-thiazepan-6-yl]-L-phenylalaninamide;

N^2-[(2*S*)-2-hydroxy-4-methylpentanoyl]-N^1-[(6*R*,7*R*)-5-oxo-7-phenyl-1,4-thiazepan-6-yl]-L-phenylalaninamide;

(2*S*)-2-{[(3,5-difluorophenyl)acetyl]amino}-N-[(6*R*,7*R*)-5-oxo-7-phenyl-1,4-thiazepan-6-yl]-2-phenylacetamide;

(2*S*)-2-hydroxy-4-methyl-N-((1*S*)-2-oxo-2-{[(6*R*,7*R*)-5-oxo-7-phenyl-1,4-thiazepan-6-yl]amino}-1-phenylethyl)pentanamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(6*R*,7*R*)-5-oxo-7-phenyl-1,4-thiazepan-6-yl]-L-leucinamide;

N^2-[(2*S*)-2-hydroxy-4-methylpentanoyl]-N^1-[(6*R*,7*R*)-5-oxo-7-phenyl-1,4-thiazepan-6-yl]-L-leucinamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(6*R*,7*R*)-5-oxo-7-phenyl-1,4-thiazepan-6-yl]-L-valinamide;

N^2-[(2*S*)-2-hydroxy-4-methylpentanoyl]-N^1-[(6*R*,7*R*)-5-oxo-7-phenyl-1,4-thiazepan-6-yl]-L-valinamide;

N^1-[(2*R*,3*S*)-7-chloro-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-N^2-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

(2*S*)-N-((1*S*)-2-{[(2*R*,3*S*)-7-chloro-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]amino}-2-oxo-1-phenylethyl)-2-hydroxy-4-methylpentanamide;

(2*S*)-2-{[(3,5-difluorophenyl)acetyl]amino}-N-[(2*R*,3*S*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-2-phenylacetamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*S*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-serinamide;

(2*S*)-2-cyclohexyl-2-{[(3,5-difluorophenyl)acetyl]amino}-N-[(2*R*,3*S*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]acetamide;

(2*S*)-N-((1*S*)-1-cyclohexyl-2-oxo-2-{[(2*R*,3*S*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]amino}ethyl)-2-hydroxy-4-methylpentanamide;

3-cyclohexyl-N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(6*R*,7*R*)-5-oxo-7-phenyl-1,4-thiazepan-6-yl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*S*)-5-(2-morpholin-4-ylethyl)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*S*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-leucinamide;

(2*S*)-2-{[(3,5-difluorophenyl)acetyl]amino}-2-(4-fluorophenyl)-N-[(2*R*,3*S*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]acetamide;

(2*S*)-2-[(cyclohexylacetyl)amino]-2-(4-fluorophenyl)-N-[(2*R*,3*S*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]acetamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*S*)-4-oxo-2-phenyl-5-prop-2-yn-1-yl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*S*)-7-methoxy-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*S*)-5-isopropyl-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-alaninamide;

methyl [(2*R*,3*S*)-3-({N-[(3,5-difluorophenyl)acetyl]-L-alanyl}amino)-4-oxo-2-phenyl-3,4-dihydro-1,5-benzoxazepin-5(2H)-yl]acetate;

[(2*R*,3*S*)-3-({N-[(3,5-difluorophenyl)acetyl]-L-alanyl}amino)-4-oxo-2-phenyl-3,4-dihydro-1,5-benzoxazepin-5(2H)-yl]acetic acid;

N^1-[(2*R*,3*S*)-5-(cyclopropylmethyl)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-N^2-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^1-[(2*R*,3*S*)-5-(cyclopropylmethyl)-7-methoxy-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-N^2-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^1-[(2*R*,3*S*)-5-(2-azetidin-1-yl-2-oxoethyl)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-N^2-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*S*)-7-fluoro-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-alaninamide;

(2*S*)-N-((1*S*)-2-{[(2*R*,3*S*)-7-fluoro-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]amino}-2-oxo-1-phenylethyl)-2-hydroxy-4-methylpentanamide;

N^2-[(2*R*)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(2*R*,3*S*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-alaninamide;

N^2-[(2*S*)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-N^1-[(2*R*,3*S*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(3*S*,4*R*)-2-oxo-4-phenyl-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(3*S*,4*R*)-8-fluoro-1-methyl-2-oxo-4-phenyl-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]-L-alaninamide;

(2*S*)-N-((1*S*)-2-{[(3*S*,4*R*)-8-fluoro-2-oxo-4-phenyl-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]amino}-2-oxo-1-phenylethyl)-2-hydroxy-4-methylpentanamide;

(2*S*)-2-hydroxy-4-methyl-N-((1*S*)-2-oxo-2-{[(3*S*,4*R*)-2-oxo-4-phenyl-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]amino}-1-phenylethyl)pentanamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(3*S*,4*R*)-2-oxo-4-phenyl-1-prop-2-yn-1-yl-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]-L-alaninamide;

N^1-[(3*S*,4*R*)-1-(cyclopropylmethyl)-2-oxo-4-phenyl-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]-N^2-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(3*S*,4*R*)-1-isopropyl-2-oxo-4-phenyl-2,3,4,5-tetrahydro-1H-1-benzazepin-3-yl]-L-alaninamide;

N^2-[(2*S*)-2-hydroxy-4-methyl-1-oxopentyl]-N^1-[(2*R*,3*R*)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N^1-[(2*R*,3*R*)-2-(2-chlorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N^2-[(2*S*)-2-hydroxy-4-methyl-1-oxopentyl]-L-alaninamide;

N^1-[(2*R*,3*R*)-2-(2-chlorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N^2-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^1-[(2*R*,3*R*)-7-chloro-5-methyl-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N^2-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*R*)-2-(2-fluorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*R*)-2-(4-fluorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N^1-[(2*R*,3*R*)-7-chloro-2-(2,5-difluorophenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N^2-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^2-[(2*S*)-2-hydroxy-4-methyl-1-oxopentyl]-N^1-[(6*R*,7*R*)-5-oxo-7-phenyl-1,4-thiazepan-6-yl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*S*,3*R*)-2-(3-methyl-2-thienyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*S*,3*R*)-2-(4-methyl-2-thienyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

Methyl 5-[(2*S*,3*R*)-3-({N-[(3,5-difluorophenyl)acetyl]-L-alanyl}amino)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-2-yl]thiophene-3-carboxylate;

N^1-[(2*R*,3*R*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N^2-(phenylacetyl)-L-alaninamide;

N^1-[(2*R*,3*R*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N^2-(2-phenylethyl)-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*S*,3*R*)-4-oxo-2-(2-thienyl)-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*R*)-4-oxo-2-(3-thienyl)-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*S*,3*R*)-2-(2-furyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*R*)-2-(3-furyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N^1-[(2*S*,3*R*)-2-(5-bromo-2-thienyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N^2-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N^1-[(2*S*,3*R*)-2-(4-bromo-2-thienyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-N^2-[(3,5-difluorophenyl)acetyl]-L-alaninamide;

N-[(3,5-difluorophenyl)acetyl]-N-[(2*R*,3*R*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-phenylalaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*R*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]glycinamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*R*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-valinamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*R*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-leucinamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*R*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-methioninamide;

N^2-[(3,5-difluorophenyl)acetyl]-3-(1H-indol-2-yl)-N^1-[(2*R*,3*R*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-alaninamide;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*R*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-a-asparagine;

N^2-[(3,5-difluorophenyl)acetyl]-N^1-[(2*R*,3*R*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl]-L-a-glutamine;

N^1-[(2*R*,3*S*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-N^2-(phenylacetyl)-L-alaninamide;

N^2-[(2-fluorophenyl)acetyl]-N^1-[(2*R*,3*S*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-alaninamide;

N^2-[(3-fluorophenyl)acetyl]-N^1-[(2*R*,3*S*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-alaninamide;

N^2-[(4-fluorophenyl)acetyl]-N^1-[(2*R*,3*S*)-4-oxo-2-phenyl-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]-L-alaninamide;

N^1-[(2*R*,3*S*,5a*S*,9a*S*)-5-(cyclopropylmethyl)-4-oxo-2-phenyldecahydro-1,5-benzoxazepin-3-yl]-N^2-[(3,5-difluorophenyl)acetyl]-L-alaninamide.

or a pharmaceutical acceptable salt thereof.

25. A compound according to any one of claims 1 to 24, for use as a medicament.

26. The use of a compound as defined in any one of claims 1 to 24, in the manufacture of a medicament for the treatment or prophylaxis of disorders associated with β-amyloid production, Alzheimer's disease, or Down's Syndrome.

27. A method for the treatment of neurological disorders associated with β-amyloid production comprising administering to a host in need of such treatment a therapeutically effective amount of a compound in any one of claims 1 to 24.

28. A method for inhibiting γ-secretase activity comprising administering to a host in need of such inhibition a therapeutically effective amount of a compound in any one of claims 1 to 24 that inhibits γ-secretase activity.

29. A method for the treatment or prophylaxis of Alzheimer's disease, or Down's Syndrome comprising adminstering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt as claimed in any one of claims 1 to 24.

30. A pharmaceutical composition comprisisng a compound of formula (I), as defined in any one of claims 1 to 24, together with at least one phamraceutically acceptable carrier, diluent or excipent.